Interim Report 2026
Filed with HKEX · Stock code 2105 · · 59 pages · English
Definitions Corporate Information Business Highlights Financial Highlights Management Discussion and Analysis Corporate Governance and Other Information Independent Review Report Consolidated Statement of Profit or Loss and Other Comprehensive Income Consolidated Statement of Financial Position Consolidated Statement of Changes in Equity Condensed Consolidated Cash Flow Statement Notes to the Unau
Earlier from Laekna
- New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
- ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
- Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
- Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
- Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
Later from Laekna
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement updates on the 24-week monotherapy study of LAE102 showed promising weight losses favorable changes in body composition and well tolerated safety profile
Follow Laekna into a list and get an email when it puts out news.
Follow Laekna